nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—Protein Kinase Inhibitors—Temsirolimus—kidney cancer	0.157	0.344	CiPCiCtD
Nilotinib—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.119	0.261	CiPCiCtD
Nilotinib—Protein Kinase Inhibitors—Pazopanib—kidney cancer	0.0903	0.198	CiPCiCtD
Nilotinib—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.0903	0.198	CiPCiCtD
Nilotinib—BRAF—kidney cancer	0.0471	0.29	CbGaD
Nilotinib—KIT—kidney cancer	0.0378	0.232	CbGaD
Nilotinib—CA9—kidney cancer	0.0363	0.223	CbGaD
Nilotinib—CA2—kidney cancer	0.0326	0.201	CbGaD
Nilotinib—MAPK11—Sorafenib—kidney cancer	0.0121	0.0489	CbGbCtD
Nilotinib—TIE1—Sorafenib—kidney cancer	0.0121	0.0489	CbGbCtD
Nilotinib—LYN—Pazopanib—kidney cancer	0.0106	0.0428	CbGbCtD
Nilotinib—EPHB6—Pazopanib—kidney cancer	0.0106	0.0428	CbGbCtD
Nilotinib—CSF1R—Pazopanib—kidney cancer	0.00951	0.0384	CbGbCtD
Nilotinib—KIT—Pazopanib—kidney cancer	0.00951	0.0384	CbGbCtD
Nilotinib—PDGFRA—Pazopanib—kidney cancer	0.00951	0.0384	CbGbCtD
Nilotinib—ABCB1—kidney cancer	0.0087	0.0536	CbGaD
Nilotinib—PDGFRB—Pazopanib—kidney cancer	0.00866	0.035	CbGbCtD
Nilotinib—LCK—Pazopanib—kidney cancer	0.00866	0.035	CbGbCtD
Nilotinib—MAP2K5—Pazopanib—kidney cancer	0.00866	0.035	CbGbCtD
Nilotinib—BRAF—Sorafenib—kidney cancer	0.00804	0.0325	CbGbCtD
Nilotinib—MAP4K1—Sunitinib—kidney cancer	0.00779	0.0315	CbGbCtD
Nilotinib—EPHA6—Erlotinib—kidney cancer	0.00755	0.0305	CbGbCtD
Nilotinib—ABL2—Erlotinib—kidney cancer	0.00679	0.0274	CbGbCtD
Nilotinib—MAP2K5—Erlotinib—kidney cancer	0.00618	0.025	CbGbCtD
Nilotinib—EPHA6—Sorafenib—kidney cancer	0.00614	0.0248	CbGbCtD
Nilotinib—EPHB6—Sorafenib—kidney cancer	0.00614	0.0248	CbGbCtD
Nilotinib—FGR—Sunitinib—kidney cancer	0.00563	0.0227	CbGbCtD
Nilotinib—CSF1R—Sorafenib—kidney cancer	0.00552	0.0223	CbGbCtD
Nilotinib—KIT—Sorafenib—kidney cancer	0.00552	0.0223	CbGbCtD
Nilotinib—PDGFRA—Sorafenib—kidney cancer	0.00552	0.0223	CbGbCtD
Nilotinib—MAP2K5—Sorafenib—kidney cancer	0.00502	0.0203	CbGbCtD
Nilotinib—PDGFRB—Sorafenib—kidney cancer	0.00502	0.0203	CbGbCtD
Nilotinib—EPHB6—Sunitinib—kidney cancer	0.00498	0.0201	CbGbCtD
Nilotinib—BLK—Sunitinib—kidney cancer	0.00498	0.0201	CbGbCtD
Nilotinib—ABL1—Erlotinib—kidney cancer	0.00491	0.0198	CbGbCtD
Nilotinib—CSF1R—Sunitinib—kidney cancer	0.00447	0.0181	CbGbCtD
Nilotinib—PDGFRA—Sunitinib—kidney cancer	0.00447	0.0181	CbGbCtD
Nilotinib—KIT—Sunitinib—kidney cancer	0.00447	0.0181	CbGbCtD
Nilotinib—PDGFRB—Sunitinib—kidney cancer	0.00407	0.0164	CbGbCtD
Nilotinib—MAP2K5—Sunitinib—kidney cancer	0.00407	0.0164	CbGbCtD
Nilotinib—UGT1A1—Pazopanib—kidney cancer	0.00286	0.0115	CbGbCtD
Nilotinib—UGT1A1—Erlotinib—kidney cancer	0.00204	0.00823	CbGbCtD
Nilotinib—UGT1A1—Sorafenib—kidney cancer	0.00166	0.00669	CbGbCtD
Nilotinib—ABCG2—Pazopanib—kidney cancer	0.00157	0.00635	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—kidney cancer	0.00144	0.0058	CbGbCtD
Nilotinib—ABCG2—Erlotinib—kidney cancer	0.00112	0.00453	CbGbCtD
Nilotinib—ABCB1—Temsirolimus—kidney cancer	0.00108	0.00436	CbGbCtD
Nilotinib—ABCG2—Paclitaxel—kidney cancer	0.00103	0.00415	CbGbCtD
Nilotinib—CA2—collecting duct of renal tubule—kidney cancer	0.00103	0.0585	CbGeAlD
Nilotinib—CYP2D6—Temsirolimus—kidney cancer	0.00102	0.0041	CbGbCtD
Nilotinib—CYP3A4—Everolimus—kidney cancer	0.000956	0.00386	CbGbCtD
Nilotinib—ABCG2—Sorafenib—kidney cancer	0.000911	0.00368	CbGbCtD
Nilotinib—ABCG2—Vincristine—kidney cancer	0.000885	0.00357	CbGbCtD
Nilotinib—CYP2C8—Pazopanib—kidney cancer	0.000837	0.00338	CbGbCtD
Nilotinib—ABCG2—Sunitinib—kidney cancer	0.000738	0.00298	CbGbCtD
Nilotinib—UGT1A1—urine—kidney cancer	0.000737	0.0421	CbGeAlD
Nilotinib—CYP3A4—Temsirolimus—kidney cancer	0.000646	0.00261	CbGbCtD
Nilotinib—CYP2B6—Sorafenib—kidney cancer	0.000641	0.00259	CbGbCtD
Nilotinib—CYP2C9—Capecitabine—kidney cancer	0.000609	0.00246	CbGbCtD
Nilotinib—CYP2C8—Erlotinib—kidney cancer	0.000597	0.00241	CbGbCtD
Nilotinib—ABCB1—Pazopanib—kidney cancer	0.000566	0.00229	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—kidney cancer	0.000553	0.00223	CbGbCtD
Nilotinib—CYP2C8—Paclitaxel—kidney cancer	0.000547	0.00221	CbGbCtD
Nilotinib—CYP2D6—Pazopanib—kidney cancer	0.000534	0.00216	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—kidney cancer	0.000518	0.00209	CbGbCtD
Nilotinib—CYP2C8—Sorafenib—kidney cancer	0.000485	0.00196	CbGbCtD
Nilotinib—FRK—renal system—kidney cancer	0.000475	0.0271	CbGeAlD
Nilotinib—FRK—gonad—kidney cancer	0.000426	0.0243	CbGeAlD
Nilotinib—ABCB1—Gemcitabine—kidney cancer	0.000409	0.00165	CbGbCtD
Nilotinib—ABCB1—Erlotinib—kidney cancer	0.000404	0.00163	CbGbCtD
Nilotinib—CDC42BPB—renal system—kidney cancer	0.0004	0.0229	CbGeAlD
Nilotinib—CYP2B6—Doxorubicin—kidney cancer	0.000389	0.00157	CbGbCtD
Nilotinib—CYP2C9—Paclitaxel—kidney cancer	0.000381	0.00154	CbGbCtD
Nilotinib—CYP2D6—Erlotinib—kidney cancer	0.000381	0.00154	CbGbCtD
Nilotinib—CDC42BPB—cortex of kidney—kidney cancer	0.000377	0.0215	CbGeAlD
Nilotinib—ABCB1—Paclitaxel—kidney cancer	0.00037	0.00149	CbGbCtD
Nilotinib—MAPK8—renal system—kidney cancer	0.000362	0.0207	CbGeAlD
Nilotinib—CDC42BPB—gonad—kidney cancer	0.000359	0.0205	CbGeAlD
Nilotinib—CDC42BPB—cardiac atrium—kidney cancer	0.000358	0.0205	CbGeAlD
Nilotinib—MAPK8—kidney—kidney cancer	0.00035	0.02	CbGeAlD
Nilotinib—MAPK8—cortex of kidney—kidney cancer	0.000341	0.0195	CbGeAlD
Nilotinib—CYP3A4—Pazopanib—kidney cancer	0.000339	0.00137	CbGbCtD
Nilotinib—CYP2C9—Sorafenib—kidney cancer	0.000339	0.00137	CbGbCtD
Nilotinib—ABCB1—Sorafenib—kidney cancer	0.000329	0.00133	CbGbCtD
Nilotinib—MAPK8—gonad—kidney cancer	0.000325	0.0185	CbGeAlD
Nilotinib—EPHA6—gonad—kidney cancer	0.000325	0.0185	CbGeAlD
Nilotinib—ABCB1—Vinblastine—kidney cancer	0.000324	0.00131	CbGbCtD
Nilotinib—Ponatinib—KDR—kidney cancer	0.000323	0.237	CrCbGaD
Nilotinib—ABCB1—Vincristine—kidney cancer	0.000319	0.00129	CbGbCtD
Nilotinib—CYP2C9—urine—kidney cancer	0.00031	0.0177	CbGeAlD
Nilotinib—CYP2D6—Sorafenib—kidney cancer	0.00031	0.00125	CbGbCtD
Nilotinib—CYP2D6—Vinblastine—kidney cancer	0.000306	0.00124	CbGbCtD
Nilotinib—Ponatinib—KIT—kidney cancer	0.000305	0.224	CrCbGaD
Nilotinib—TIE1—cardiac atrium—kidney cancer	0.000281	0.016	CbGeAlD
Nilotinib—CA7—renal system—kidney cancer	0.000268	0.0153	CbGeAlD
Nilotinib—ABCB1—Sunitinib—kidney cancer	0.000266	0.00108	CbGbCtD
Nilotinib—CA7—kidney—kidney cancer	0.00026	0.0148	CbGeAlD
Nilotinib—CYP3A4—Erlotinib—kidney cancer	0.000242	0.000978	CbGbCtD
Nilotinib—EPHB4—nephron tubule—kidney cancer	0.00024	0.0137	CbGeAlD
Nilotinib—CYP3A4—urine—kidney cancer	0.000236	0.0135	CbGeAlD
Nilotinib—EPHA2—nephron tubule—kidney cancer	0.000235	0.0134	CbGeAlD
Nilotinib—CYP2D6—urine—kidney cancer	0.000232	0.0133	CbGeAlD
Nilotinib—MAPK14—renal system—kidney cancer	0.00023	0.0131	CbGeAlD
Nilotinib—EPHA4—gonad—kidney cancer	0.000224	0.0128	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—kidney cancer	0.000223	0.0127	CbGeAlD
Nilotinib—MAPK14—kidney—kidney cancer	0.000222	0.0127	CbGeAlD
Nilotinib—CYP3A4—Paclitaxel—kidney cancer	0.000222	0.000895	CbGbCtD
Nilotinib—CA3—cardiac atrium—kidney cancer	0.000221	0.0126	CbGeAlD
Nilotinib—EPHB4—renal system—kidney cancer	0.000218	0.0124	CbGeAlD
Nilotinib—EPHB4—kidney—kidney cancer	0.000211	0.012	CbGeAlD
Nilotinib—TEK—renal system—kidney cancer	0.000209	0.0119	CbGeAlD
Nilotinib—EPHB4—cortex of kidney—kidney cancer	0.000205	0.0117	CbGeAlD
Nilotinib—TEK—kidney—kidney cancer	0.000202	0.0115	CbGeAlD
Nilotinib—CA14—cardiac atrium—kidney cancer	0.0002	0.0114	CbGeAlD
Nilotinib—ABCB1—Doxorubicin—kidney cancer	0.000199	0.000806	CbGbCtD
Nilotinib—CYP3A4—Sorafenib—kidney cancer	0.000197	0.000795	CbGbCtD
Nilotinib—TEK—cortex of kidney—kidney cancer	0.000196	0.0112	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—kidney cancer	0.000195	0.0111	CbGeAlD
Nilotinib—CYP3A4—Vinblastine—kidney cancer	0.000194	0.000785	CbGbCtD
Nilotinib—EPHA2—cardiac atrium—kidney cancer	0.000191	0.0109	CbGeAlD
Nilotinib—CYP3A4—Vincristine—kidney cancer	0.000191	0.000772	CbGbCtD
Nilotinib—PDGFRA—renal system—kidney cancer	0.000189	0.0108	CbGeAlD
Nilotinib—Imatinib—KIT—kidney cancer	0.000188	0.138	CrCbGaD
Nilotinib—CYP2D6—Doxorubicin—kidney cancer	0.000188	0.000759	CbGbCtD
Nilotinib—EPHB6—cortex of kidney—kidney cancer	0.000188	0.0107	CbGeAlD
Nilotinib—TEK—cardiac atrium—kidney cancer	0.000187	0.0107	CbGeAlD
Nilotinib—Imatinib—CA9—kidney cancer	0.000181	0.133	CrCbGaD
Nilotinib—UGT1A1—renal system—kidney cancer	0.00018	0.0103	CbGeAlD
Nilotinib—EPHB6—cardiac atrium—kidney cancer	0.000179	0.0102	CbGeAlD
Nilotinib—CA12—renal system—kidney cancer	0.000174	0.00996	CbGeAlD
Nilotinib—UGT1A1—kidney—kidney cancer	0.000174	0.00995	CbGeAlD
Nilotinib—PDGFRA—gonad—kidney cancer	0.000169	0.00968	CbGeAlD
Nilotinib—CA12—kidney—kidney cancer	0.000169	0.00963	CbGeAlD
Nilotinib—KIT—nephron tubule—kidney cancer	0.000166	0.00949	CbGeAlD
Nilotinib—Imatinib—CA2—kidney cancer	0.000162	0.119	CrCbGaD
Nilotinib—MAP2K5—cortex of kidney—kidney cancer	0.00016	0.00916	CbGeAlD
Nilotinib—CYP3A4—Sunitinib—kidney cancer	0.00016	0.000644	CbGbCtD
Nilotinib—MAP2K5—cardiac atrium—kidney cancer	0.000153	0.00872	CbGeAlD
Nilotinib—KIT—renal system—kidney cancer	0.000151	0.00863	CbGeAlD
Nilotinib—CSF1R—gonad—kidney cancer	0.000149	0.00852	CbGeAlD
Nilotinib—CSF1R—cardiac atrium—kidney cancer	0.000149	0.00851	CbGeAlD
Nilotinib—PDGFRB—renal system—kidney cancer	0.000148	0.00842	CbGeAlD
Nilotinib—KIT—kidney—kidney cancer	0.000146	0.00834	CbGeAlD
Nilotinib—ABL1—nephron tubule—kidney cancer	0.000145	0.00826	CbGeAlD
Nilotinib—ABL1—Epirubicin—Doxorubicin—kidney cancer	0.000144	0.333	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—kidney cancer	0.000144	0.333	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	0.000144	0.333	CbGdCrCtD
Nilotinib—PDGFRB—kidney—kidney cancer	0.000143	0.00814	CbGeAlD
Nilotinib—KIT—cortex of kidney—kidney cancer	0.000142	0.00812	CbGeAlD
Nilotinib—PDGFRB—cortex of kidney—kidney cancer	0.000139	0.00793	CbGeAlD
Nilotinib—CA1—renal system—kidney cancer	0.000138	0.00789	CbGeAlD
Nilotinib—KIT—gonad—kidney cancer	0.000135	0.00773	CbGeAlD
Nilotinib—CA1—kidney—kidney cancer	0.000134	0.00763	CbGeAlD
Nilotinib—PDGFRB—gonad—kidney cancer	0.000132	0.00755	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—kidney cancer	0.000132	0.00754	CbGeAlD
Nilotinib—ABL1—renal system—kidney cancer	0.000132	0.00751	CbGeAlD
Nilotinib—ABL1—kidney—kidney cancer	0.000127	0.00726	CbGeAlD
Nilotinib—ABL1—cortex of kidney—kidney cancer	0.000124	0.00707	CbGeAlD
Nilotinib—CYP3A4—Doxorubicin—kidney cancer	0.000119	0.000483	CbGbCtD
Nilotinib—CA4—nephron tubule—kidney cancer	0.000119	0.00678	CbGeAlD
Nilotinib—ABL1—gonad—kidney cancer	0.000118	0.00673	CbGeAlD
Nilotinib—ABL1—cardiac atrium—kidney cancer	0.000118	0.00672	CbGeAlD
Nilotinib—CA4—renal system—kidney cancer	0.000108	0.00617	CbGeAlD
Nilotinib—CA4—kidney—kidney cancer	0.000104	0.00596	CbGeAlD
Nilotinib—CA4—cortex of kidney—kidney cancer	0.000102	0.00581	CbGeAlD
Nilotinib—CA2—nephron tubule—kidney cancer	9.85e-05	0.00562	CbGeAlD
Nilotinib—CA4—cardiac atrium—kidney cancer	9.67e-05	0.00552	CbGeAlD
Nilotinib—ABCG2—nephron tubule—kidney cancer	9.12e-05	0.00521	CbGeAlD
Nilotinib—CA2—renal system—kidney cancer	8.95e-05	0.00511	CbGeAlD
Nilotinib—Imatinib—PTGS1—kidney cancer	8.91e-05	0.0654	CrCbGaD
Nilotinib—CA2—kidney—kidney cancer	8.66e-05	0.00494	CbGeAlD
Nilotinib—CYP2C8—renal system—kidney cancer	8.53e-05	0.00487	CbGeAlD
Nilotinib—CA2—cortex of kidney—kidney cancer	8.43e-05	0.00481	CbGeAlD
Nilotinib—CYP2B6—nephron tubule—kidney cancer	8.42e-05	0.00481	CbGeAlD
Nilotinib—CYP2C8—kidney—kidney cancer	8.25e-05	0.00471	CbGeAlD
Nilotinib—CA2—cardiac atrium—kidney cancer	8.02e-05	0.00458	CbGeAlD
Nilotinib—CYP2B6—renal system—kidney cancer	7.65e-05	0.00437	CbGeAlD
Nilotinib—CYP2B6—kidney—kidney cancer	7.4e-05	0.00422	CbGeAlD
Nilotinib—Ponatinib—ABCB1—kidney cancer	7.03e-05	0.0516	CrCbGaD
Nilotinib—CYP2B6—gonad—kidney cancer	6.86e-05	0.00392	CbGeAlD
Nilotinib—CYP3A4—renal system—kidney cancer	5.78e-05	0.0033	CbGeAlD
Nilotinib—CYP2D6—renal system—kidney cancer	5.68e-05	0.00325	CbGeAlD
Nilotinib—CYP3A4—kidney—kidney cancer	5.58e-05	0.00319	CbGeAlD
Nilotinib—CYP2D6—kidney—kidney cancer	5.5e-05	0.00314	CbGeAlD
Nilotinib—ABCB1—nephron tubule—kidney cancer	4.5e-05	0.00257	CbGeAlD
Nilotinib—Imatinib—ABCB1—kidney cancer	4.33e-05	0.0318	CrCbGaD
Nilotinib—ABCB1—renal system—kidney cancer	4.09e-05	0.00233	CbGeAlD
Nilotinib—ABCB1—kidney—kidney cancer	3.95e-05	0.00226	CbGeAlD
Nilotinib—ABCB1—cortex of kidney—kidney cancer	3.85e-05	0.0022	CbGeAlD
Nilotinib—ABCB1—gonad—kidney cancer	3.67e-05	0.00209	CbGeAlD
Nilotinib—Oedema—Paclitaxel—kidney cancer	1.09e-05	0.000174	CcSEcCtD
Nilotinib—Abdominal pain—Vincristine—kidney cancer	1.08e-05	0.000174	CcSEcCtD
Nilotinib—Body temperature increased—Vincristine—kidney cancer	1.08e-05	0.000174	CcSEcCtD
Nilotinib—Infection—Paclitaxel—kidney cancer	1.08e-05	0.000173	CcSEcCtD
Nilotinib—Flatulence—Capecitabine—kidney cancer	1.08e-05	0.000173	CcSEcCtD
Nilotinib—Dry skin—Doxorubicin—kidney cancer	1.08e-05	0.000172	CcSEcCtD
Nilotinib—Dysgeusia—Capecitabine—kidney cancer	1.07e-05	0.000172	CcSEcCtD
Nilotinib—Dizziness—Sunitinib—kidney cancer	1.07e-05	0.000172	CcSEcCtD
Nilotinib—Feeling abnormal—Gemcitabine—kidney cancer	1.07e-05	0.000172	CcSEcCtD
Nilotinib—Shock—Paclitaxel—kidney cancer	1.07e-05	0.000172	CcSEcCtD
Nilotinib—Vomiting—Sorafenib—kidney cancer	1.07e-05	0.000171	CcSEcCtD
Nilotinib—Abdominal pain upper—Doxorubicin—kidney cancer	1.07e-05	0.000171	CcSEcCtD
Nilotinib—Nervous system disorder—Paclitaxel—kidney cancer	1.07e-05	0.000171	CcSEcCtD
Nilotinib—Hypokalaemia—Doxorubicin—kidney cancer	1.07e-05	0.000171	CcSEcCtD
Nilotinib—Thrombocytopenia—Paclitaxel—kidney cancer	1.07e-05	0.000171	CcSEcCtD
Nilotinib—Tachycardia—Paclitaxel—kidney cancer	1.06e-05	0.00017	CcSEcCtD
Nilotinib—Rash—Sorafenib—kidney cancer	1.06e-05	0.00017	CcSEcCtD
Nilotinib—Dermatitis—Sorafenib—kidney cancer	1.06e-05	0.00017	CcSEcCtD
Nilotinib—Back pain—Capecitabine—kidney cancer	1.06e-05	0.00017	CcSEcCtD
Nilotinib—Breast disorder—Doxorubicin—kidney cancer	1.06e-05	0.00017	CcSEcCtD
Nilotinib—Skin disorder—Paclitaxel—kidney cancer	1.06e-05	0.000169	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	1.06e-05	0.000169	CcSEcCtD
Nilotinib—Headache—Sorafenib—kidney cancer	1.06e-05	0.000169	CcSEcCtD
Nilotinib—Muscle spasms—Capecitabine—kidney cancer	1.05e-05	0.000169	CcSEcCtD
Nilotinib—Hyperhidrosis—Paclitaxel—kidney cancer	1.05e-05	0.000169	CcSEcCtD
Nilotinib—Diarrhoea—Dactinomycin—kidney cancer	1.05e-05	0.000168	CcSEcCtD
Nilotinib—Nasopharyngitis—Doxorubicin—kidney cancer	1.05e-05	0.000168	CcSEcCtD
Nilotinib—Anorexia—Paclitaxel—kidney cancer	1.04e-05	0.000166	CcSEcCtD
Nilotinib—Gastritis—Doxorubicin—kidney cancer	1.04e-05	0.000166	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	1.03e-05	0.000165	CcSEcCtD
Nilotinib—Muscular weakness—Doxorubicin—kidney cancer	1.03e-05	0.000165	CcSEcCtD
Nilotinib—Vision blurred—Capecitabine—kidney cancer	1.03e-05	0.000165	CcSEcCtD
Nilotinib—Vomiting—Sunitinib—kidney cancer	1.03e-05	0.000165	CcSEcCtD
Nilotinib—Body temperature increased—Gemcitabine—kidney cancer	1.03e-05	0.000165	CcSEcCtD
Nilotinib—Tremor—Capecitabine—kidney cancer	1.03e-05	0.000164	CcSEcCtD
Nilotinib—Rash—Sunitinib—kidney cancer	1.02e-05	0.000164	CcSEcCtD
Nilotinib—Dermatitis—Sunitinib—kidney cancer	1.02e-05	0.000163	CcSEcCtD
Nilotinib—Abdominal distension—Doxorubicin—kidney cancer	1.02e-05	0.000163	CcSEcCtD
Nilotinib—Hypotension—Paclitaxel—kidney cancer	1.02e-05	0.000163	CcSEcCtD
Nilotinib—Ill-defined disorder—Capecitabine—kidney cancer	1.02e-05	0.000163	CcSEcCtD
Nilotinib—Headache—Sunitinib—kidney cancer	1.02e-05	0.000163	CcSEcCtD
Nilotinib—Influenza—Doxorubicin—kidney cancer	1.01e-05	0.000162	CcSEcCtD
Nilotinib—Anaemia—Capecitabine—kidney cancer	1.01e-05	0.000162	CcSEcCtD
Nilotinib—Hypersensitivity—Vincristine—kidney cancer	1.01e-05	0.000162	CcSEcCtD
Nilotinib—Eosinophilia—Doxorubicin—kidney cancer	1e-05	0.000161	CcSEcCtD
Nilotinib—Nausea—Sorafenib—kidney cancer	1e-05	0.00016	CcSEcCtD
Nilotinib—Pancreatitis—Doxorubicin—kidney cancer	9.94e-06	0.000159	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	9.93e-06	0.000159	CcSEcCtD
Nilotinib—Malaise—Capecitabine—kidney cancer	9.88e-06	0.000158	CcSEcCtD
Nilotinib—Angina pectoris—Doxorubicin—kidney cancer	9.88e-06	0.000158	CcSEcCtD
Nilotinib—Insomnia—Paclitaxel—kidney cancer	9.86e-06	0.000158	CcSEcCtD
Nilotinib—Vertigo—Capecitabine—kidney cancer	9.85e-06	0.000158	CcSEcCtD
Nilotinib—Asthenia—Vincristine—kidney cancer	9.85e-06	0.000157	CcSEcCtD
Nilotinib—Syncope—Capecitabine—kidney cancer	9.83e-06	0.000157	CcSEcCtD
Nilotinib—Leukopenia—Capecitabine—kidney cancer	9.81e-06	0.000157	CcSEcCtD
Nilotinib—Paraesthesia—Paclitaxel—kidney cancer	9.79e-06	0.000157	CcSEcCtD
Nilotinib—Vomiting—Dactinomycin—kidney cancer	9.77e-06	0.000156	CcSEcCtD
Nilotinib—Bronchitis—Doxorubicin—kidney cancer	9.75e-06	0.000156	CcSEcCtD
Nilotinib—Dyspnoea—Paclitaxel—kidney cancer	9.72e-06	0.000155	CcSEcCtD
Nilotinib—Palpitations—Capecitabine—kidney cancer	9.68e-06	0.000155	CcSEcCtD
Nilotinib—Rash—Dactinomycin—kidney cancer	9.68e-06	0.000155	CcSEcCtD
Nilotinib—Nausea—Sunitinib—kidney cancer	9.64e-06	0.000154	CcSEcCtD
Nilotinib—Loss of consciousness—Capecitabine—kidney cancer	9.63e-06	0.000154	CcSEcCtD
Nilotinib—Pancytopenia—Doxorubicin—kidney cancer	9.63e-06	0.000154	CcSEcCtD
Nilotinib—Dyspepsia—Paclitaxel—kidney cancer	9.59e-06	0.000153	CcSEcCtD
Nilotinib—Cough—Capecitabine—kidney cancer	9.56e-06	0.000153	CcSEcCtD
Nilotinib—Dysuria—Doxorubicin—kidney cancer	9.48e-06	0.000152	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—kidney cancer	9.48e-06	0.000152	CcSEcCtD
Nilotinib—Decreased appetite—Paclitaxel—kidney cancer	9.47e-06	0.000152	CcSEcCtD
Nilotinib—Hypertension—Capecitabine—kidney cancer	9.46e-06	0.000151	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—kidney cancer	9.42e-06	0.000151	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.41e-06	0.000151	CcSEcCtD
Nilotinib—Fatigue—Paclitaxel—kidney cancer	9.4e-06	0.00015	CcSEcCtD
Nilotinib—Diarrhoea—Vincristine—kidney cancer	9.39e-06	0.00015	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—kidney cancer	9.37e-06	0.00015	CcSEcCtD
Nilotinib—Asthenia—Gemcitabine—kidney cancer	9.34e-06	0.000149	CcSEcCtD
Nilotinib—Myalgia—Capecitabine—kidney cancer	9.33e-06	0.000149	CcSEcCtD
Nilotinib—Arthralgia—Capecitabine—kidney cancer	9.33e-06	0.000149	CcSEcCtD
Nilotinib—Chest pain—Capecitabine—kidney cancer	9.33e-06	0.000149	CcSEcCtD
Nilotinib—Pain—Paclitaxel—kidney cancer	9.32e-06	0.000149	CcSEcCtD
Nilotinib—Constipation—Paclitaxel—kidney cancer	9.32e-06	0.000149	CcSEcCtD
Nilotinib—Anxiety—Capecitabine—kidney cancer	9.3e-06	0.000149	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	9.27e-06	0.000148	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—kidney cancer	9.25e-06	0.000148	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—kidney cancer	9.23e-06	0.000148	CcSEcCtD
Nilotinib—Discomfort—Capecitabine—kidney cancer	9.22e-06	0.000147	CcSEcCtD
Nilotinib—Pruritus—Gemcitabine—kidney cancer	9.21e-06	0.000147	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—kidney cancer	9.17e-06	0.000147	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—kidney cancer	9.15e-06	0.000146	CcSEcCtD
Nilotinib—Dry mouth—Capecitabine—kidney cancer	9.12e-06	0.000146	CcSEcCtD
Nilotinib—Nausea—Dactinomycin—kidney cancer	9.12e-06	0.000146	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—kidney cancer	9.09e-06	0.000145	CcSEcCtD
Nilotinib—Dizziness—Vincristine—kidney cancer	9.07e-06	0.000145	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—kidney cancer	9.04e-06	0.000145	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—kidney cancer	9.04e-06	0.000145	CcSEcCtD
Nilotinib—Confusional state—Capecitabine—kidney cancer	9.02e-06	0.000144	CcSEcCtD
Nilotinib—Feeling abnormal—Paclitaxel—kidney cancer	8.98e-06	0.000144	CcSEcCtD
Nilotinib—Oedema—Capecitabine—kidney cancer	8.94e-06	0.000143	CcSEcCtD
Nilotinib—Gastrointestinal pain—Paclitaxel—kidney cancer	8.91e-06	0.000143	CcSEcCtD
Nilotinib—Diarrhoea—Gemcitabine—kidney cancer	8.91e-06	0.000142	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—kidney cancer	8.89e-06	0.000142	CcSEcCtD
Nilotinib—Infection—Capecitabine—kidney cancer	8.89e-06	0.000142	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—kidney cancer	8.86e-06	0.000142	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—kidney cancer	8.81e-06	0.000141	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—kidney cancer	8.81e-06	0.000141	CcSEcCtD
Nilotinib—Shock—Capecitabine—kidney cancer	8.8e-06	0.000141	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—kidney cancer	8.79e-06	0.000141	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—kidney cancer	8.79e-06	0.000141	CcSEcCtD
Nilotinib—Nervous system disorder—Capecitabine—kidney cancer	8.77e-06	0.00014	CcSEcCtD
Nilotinib—Thrombocytopenia—Capecitabine—kidney cancer	8.76e-06	0.00014	CcSEcCtD
Nilotinib—Tachycardia—Capecitabine—kidney cancer	8.73e-06	0.00014	CcSEcCtD
Nilotinib—Vomiting—Vincristine—kidney cancer	8.72e-06	0.00014	CcSEcCtD
Nilotinib—Skin disorder—Capecitabine—kidney cancer	8.69e-06	0.000139	CcSEcCtD
Nilotinib—Urticaria—Paclitaxel—kidney cancer	8.66e-06	0.000139	CcSEcCtD
Nilotinib—Rash—Vincristine—kidney cancer	8.65e-06	0.000138	CcSEcCtD
Nilotinib—Hyperhidrosis—Capecitabine—kidney cancer	8.65e-06	0.000138	CcSEcCtD
Nilotinib—Dermatitis—Vincristine—kidney cancer	8.64e-06	0.000138	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—kidney cancer	8.62e-06	0.000138	CcSEcCtD
Nilotinib—Body temperature increased—Paclitaxel—kidney cancer	8.62e-06	0.000138	CcSEcCtD
Nilotinib—Abdominal pain—Paclitaxel—kidney cancer	8.62e-06	0.000138	CcSEcCtD
Nilotinib—Headache—Vincristine—kidney cancer	8.6e-06	0.000138	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—kidney cancer	8.55e-06	0.000137	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—kidney cancer	8.53e-06	0.000136	CcSEcCtD
Nilotinib—Anorexia—Capecitabine—kidney cancer	8.53e-06	0.000136	CcSEcCtD
Nilotinib—Hypotension—Capecitabine—kidney cancer	8.36e-06	0.000134	CcSEcCtD
Nilotinib—Vomiting—Gemcitabine—kidney cancer	8.28e-06	0.000132	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—kidney cancer	8.26e-06	0.000132	CcSEcCtD
Nilotinib—Rash—Gemcitabine—kidney cancer	8.21e-06	0.000131	CcSEcCtD
Nilotinib—Dermatitis—Gemcitabine—kidney cancer	8.2e-06	0.000131	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—kidney cancer	8.16e-06	0.00013	CcSEcCtD
Nilotinib—Headache—Gemcitabine—kidney cancer	8.16e-06	0.00013	CcSEcCtD
Nilotinib—Nausea—Vincristine—kidney cancer	8.15e-06	0.00013	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Capecitabine—kidney cancer	8.15e-06	0.00013	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—kidney cancer	8.14e-06	0.00013	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—kidney cancer	8.12e-06	0.00013	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—kidney cancer	8.12e-06	0.00013	CcSEcCtD
Nilotinib—Insomnia—Capecitabine—kidney cancer	8.09e-06	0.000129	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—kidney cancer	8.07e-06	0.000129	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—kidney cancer	8.05e-06	0.000129	CcSEcCtD
Nilotinib—Paraesthesia—Capecitabine—kidney cancer	8.03e-06	0.000128	CcSEcCtD
Nilotinib—Hypersensitivity—Paclitaxel—kidney cancer	8.03e-06	0.000128	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—kidney cancer	8.01e-06	0.000128	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—kidney cancer	7.99e-06	0.000128	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—kidney cancer	7.97e-06	0.000128	CcSEcCtD
Nilotinib—Dyspnoea—Capecitabine—kidney cancer	7.97e-06	0.000128	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—kidney cancer	7.95e-06	0.000127	CcSEcCtD
Nilotinib—Dyspepsia—Capecitabine—kidney cancer	7.87e-06	0.000126	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—kidney cancer	7.82e-06	0.000125	CcSEcCtD
Nilotinib—Asthenia—Paclitaxel—kidney cancer	7.82e-06	0.000125	CcSEcCtD
Nilotinib—Decreased appetite—Capecitabine—kidney cancer	7.78e-06	0.000124	CcSEcCtD
Nilotinib—Nausea—Gemcitabine—kidney cancer	7.73e-06	0.000124	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Capecitabine—kidney cancer	7.72e-06	0.000124	CcSEcCtD
Nilotinib—Fatigue—Capecitabine—kidney cancer	7.71e-06	0.000123	CcSEcCtD
Nilotinib—Pruritus—Paclitaxel—kidney cancer	7.71e-06	0.000123	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—kidney cancer	7.67e-06	0.000123	CcSEcCtD
Nilotinib—Constipation—Capecitabine—kidney cancer	7.65e-06	0.000122	CcSEcCtD
Nilotinib—Pain—Capecitabine—kidney cancer	7.65e-06	0.000122	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—kidney cancer	7.58e-06	0.000121	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—kidney cancer	7.57e-06	0.000121	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—kidney cancer	7.53e-06	0.00012	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—kidney cancer	7.53e-06	0.00012	CcSEcCtD
Nilotinib—Diarrhoea—Paclitaxel—kidney cancer	7.46e-06	0.000119	CcSEcCtD
Nilotinib—Feeling abnormal—Capecitabine—kidney cancer	7.37e-06	0.000118	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—kidney cancer	7.36e-06	0.000118	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—kidney cancer	7.33e-06	0.000117	CcSEcCtD
Nilotinib—Gastrointestinal pain—Capecitabine—kidney cancer	7.31e-06	0.000117	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—kidney cancer	7.31e-06	0.000117	CcSEcCtD
Nilotinib—Chills—Doxorubicin—kidney cancer	7.28e-06	0.000116	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—kidney cancer	7.25e-06	0.000116	CcSEcCtD
Nilotinib—Dizziness—Paclitaxel—kidney cancer	7.21e-06	0.000115	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—kidney cancer	7.17e-06	0.000115	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—kidney cancer	7.11e-06	0.000114	CcSEcCtD
Nilotinib—Urticaria—Capecitabine—kidney cancer	7.11e-06	0.000114	CcSEcCtD
Nilotinib—Abdominal pain—Capecitabine—kidney cancer	7.07e-06	0.000113	CcSEcCtD
Nilotinib—Body temperature increased—Capecitabine—kidney cancer	7.07e-06	0.000113	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—kidney cancer	7.06e-06	0.000113	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—kidney cancer	7.06e-06	0.000113	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—kidney cancer	6.96e-06	0.000111	CcSEcCtD
Nilotinib—Vomiting—Paclitaxel—kidney cancer	6.93e-06	0.000111	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—kidney cancer	6.92e-06	0.000111	CcSEcCtD
Nilotinib—Rash—Paclitaxel—kidney cancer	6.87e-06	0.00011	CcSEcCtD
Nilotinib—Dermatitis—Paclitaxel—kidney cancer	6.87e-06	0.00011	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—kidney cancer	6.83e-06	0.000109	CcSEcCtD
Nilotinib—Headache—Paclitaxel—kidney cancer	6.83e-06	0.000109	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—kidney cancer	6.79e-06	0.000109	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—kidney cancer	6.66e-06	0.000106	CcSEcCtD
Nilotinib—Hypersensitivity—Capecitabine—kidney cancer	6.59e-06	0.000105	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—kidney cancer	6.55e-06	0.000105	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—kidney cancer	6.53e-06	0.000104	CcSEcCtD
Nilotinib—Nausea—Paclitaxel—kidney cancer	6.47e-06	0.000104	CcSEcCtD
Nilotinib—Asthenia—Capecitabine—kidney cancer	6.42e-06	0.000103	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—kidney cancer	6.37e-06	0.000102	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—kidney cancer	6.35e-06	0.000102	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—kidney cancer	6.34e-06	0.000101	CcSEcCtD
Nilotinib—Pruritus—Capecitabine—kidney cancer	6.33e-06	0.000101	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—kidney cancer	6.32e-06	0.000101	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—kidney cancer	6.24e-06	9.99e-05	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—kidney cancer	6.21e-06	9.93e-05	CcSEcCtD
Nilotinib—Cough—Doxorubicin—kidney cancer	6.16e-06	9.86e-05	CcSEcCtD
Nilotinib—Diarrhoea—Capecitabine—kidney cancer	6.12e-06	9.79e-05	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—kidney cancer	6.1e-06	9.76e-05	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—kidney cancer	6.01e-06	9.62e-05	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—kidney cancer	6.01e-06	9.62e-05	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—kidney cancer	6.01e-06	9.62e-05	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—kidney cancer	5.99e-06	9.59e-05	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.97e-06	9.55e-05	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—kidney cancer	5.94e-06	9.51e-05	CcSEcCtD
Nilotinib—Dizziness—Capecitabine—kidney cancer	5.91e-06	9.46e-05	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—kidney cancer	5.88e-06	9.41e-05	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—kidney cancer	5.81e-06	9.3e-05	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—kidney cancer	5.77e-06	9.22e-05	CcSEcCtD
Nilotinib—Infection—Doxorubicin—kidney cancer	5.73e-06	9.16e-05	CcSEcCtD
Nilotinib—Vomiting—Capecitabine—kidney cancer	5.69e-06	9.1e-05	CcSEcCtD
Nilotinib—Shock—Doxorubicin—kidney cancer	5.67e-06	9.07e-05	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—kidney cancer	5.65e-06	9.04e-05	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—kidney cancer	5.64e-06	9.03e-05	CcSEcCtD
Nilotinib—Rash—Capecitabine—kidney cancer	5.64e-06	9.02e-05	CcSEcCtD
Nilotinib—Dermatitis—Capecitabine—kidney cancer	5.63e-06	9.01e-05	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—kidney cancer	5.63e-06	9e-05	CcSEcCtD
Nilotinib—Headache—Capecitabine—kidney cancer	5.6e-06	8.96e-05	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—kidney cancer	5.6e-06	8.96e-05	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—kidney cancer	5.57e-06	8.92e-05	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—kidney cancer	5.5e-06	8.79e-05	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—kidney cancer	5.39e-06	8.62e-05	CcSEcCtD
Nilotinib—Nausea—Capecitabine—kidney cancer	5.31e-06	8.5e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	5.25e-06	8.4e-05	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—kidney cancer	5.21e-06	8.34e-05	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—kidney cancer	5.18e-06	8.28e-05	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—kidney cancer	5.14e-06	8.22e-05	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—kidney cancer	5.08e-06	8.12e-05	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—kidney cancer	5.01e-06	8.02e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.98e-06	7.96e-05	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—kidney cancer	4.97e-06	7.95e-05	CcSEcCtD
Nilotinib—Pain—Doxorubicin—kidney cancer	4.93e-06	7.89e-05	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—kidney cancer	4.93e-06	7.89e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—kidney cancer	4.75e-06	7.6e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—kidney cancer	4.71e-06	7.54e-05	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—kidney cancer	4.58e-06	7.33e-05	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—kidney cancer	4.56e-06	7.29e-05	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—kidney cancer	4.56e-06	7.29e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—kidney cancer	4.25e-06	6.79e-05	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—kidney cancer	4.14e-06	6.62e-05	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—kidney cancer	4.08e-06	6.53e-05	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—kidney cancer	3.94e-06	6.31e-05	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—kidney cancer	3.81e-06	6.1e-05	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—kidney cancer	3.67e-06	5.86e-05	CcSEcCtD
Nilotinib—Rash—Doxorubicin—kidney cancer	3.64e-06	5.82e-05	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—kidney cancer	3.63e-06	5.81e-05	CcSEcCtD
Nilotinib—Headache—Doxorubicin—kidney cancer	3.61e-06	5.78e-05	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—kidney cancer	3.42e-06	5.48e-05	CcSEcCtD
Nilotinib—LCK—Immune System—IL2—kidney cancer	4.07e-07	7.97e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KRAS—kidney cancer	4.07e-07	7.96e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—BCHE—kidney cancer	4.07e-07	7.96e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—BRAF—kidney cancer	4.07e-07	7.96e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—kidney cancer	4.07e-07	7.96e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RAF1—kidney cancer	4.06e-07	7.95e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KDR—kidney cancer	4.06e-07	7.95e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP1A1—kidney cancer	4.06e-07	7.94e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—kidney cancer	4.06e-07	7.94e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RELA—kidney cancer	4.04e-07	7.91e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—BCHE—kidney cancer	4.03e-07	7.89e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB2—kidney cancer	4.02e-07	7.86e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC5A5—kidney cancer	4.02e-07	7.86e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTEN—kidney cancer	4.01e-07	7.86e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—PIK3CA—kidney cancer	4.01e-07	7.84e-06	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PIK3CA—kidney cancer	4.01e-07	7.84e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4e-07	7.83e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK3—kidney cancer	3.99e-07	7.82e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC5A5—kidney cancer	3.98e-07	7.79e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—kidney cancer	3.98e-07	7.79e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MAPK1—kidney cancer	3.98e-07	7.78e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTEN—kidney cancer	3.98e-07	7.78e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK3—kidney cancer	3.97e-07	7.78e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—KRAS—kidney cancer	3.97e-07	7.77e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MTOR—kidney cancer	3.96e-07	7.76e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—JUN—kidney cancer	3.96e-07	7.75e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—PIK3CA—kidney cancer	3.95e-07	7.73e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTP1—kidney cancer	3.94e-07	7.71e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1B—kidney cancer	3.93e-07	7.69e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTNNB1—kidney cancer	3.93e-07	7.69e-06	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	3.93e-07	7.68e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MAPK1—kidney cancer	3.89e-07	7.62e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MAPK1—kidney cancer	3.88e-07	7.6e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.88e-07	7.59e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—kidney cancer	3.88e-07	7.59e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KRAS—kidney cancer	3.87e-07	7.57e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—kidney cancer	3.85e-07	7.53e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC2A1—kidney cancer	3.85e-07	7.53e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1B—kidney cancer	3.84e-07	7.52e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PTEN—kidney cancer	3.83e-07	7.5e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK1—kidney cancer	3.8e-07	7.44e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK3—kidney cancer	3.79e-07	7.41e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK1—kidney cancer	3.78e-07	7.4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MAPK3—kidney cancer	3.77e-07	7.37e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MAPK3—kidney cancer	3.76e-07	7.37e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KRAS—kidney cancer	3.76e-07	7.35e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—kidney cancer	3.75e-07	7.34e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—JUN—kidney cancer	3.74e-07	7.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KIT—kidney cancer	3.74e-07	7.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APC—kidney cancer	3.74e-07	7.32e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PIK3CA—kidney cancer	3.74e-07	7.32e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.73e-07	7.3e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—kidney cancer	3.73e-07	7.3e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1B—kidney cancer	3.72e-07	7.28e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—kidney cancer	3.71e-07	7.27e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—kidney cancer	3.68e-07	7.2e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—kidney cancer	3.67e-07	7.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—kidney cancer	3.66e-07	7.17e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—kidney cancer	3.66e-07	7.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RAF1—kidney cancer	3.66e-07	7.16e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—PIK3CA—kidney cancer	3.65e-07	7.14e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RELA—kidney cancer	3.64e-07	7.13e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—kidney cancer	3.64e-07	7.13e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—kidney cancer	3.63e-07	7.1e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—kidney cancer	3.63e-07	7.1e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTM1—kidney cancer	3.62e-07	7.09e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—kidney cancer	3.62e-07	7.08e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTEN—kidney cancer	3.62e-07	7.08e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK1—kidney cancer	3.6e-07	7.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CRABP1—kidney cancer	3.6e-07	7.05e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—kidney cancer	3.59e-07	7.03e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—kidney cancer	3.59e-07	7.02e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MAPK1—kidney cancer	3.58e-07	7.01e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RAF1—kidney cancer	3.58e-07	7.01e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—kidney cancer	3.57e-07	6.99e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MTOR—kidney cancer	3.57e-07	6.99e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RELA—kidney cancer	3.57e-07	6.98e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—kidney cancer	3.56e-07	6.97e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PIK3CA—kidney cancer	3.55e-07	6.96e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—kidney cancer	3.55e-07	6.95e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—kidney cancer	3.54e-07	6.94e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—JUN—kidney cancer	3.54e-07	6.93e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—kidney cancer	3.54e-07	6.92e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BRAF—kidney cancer	3.52e-07	6.88e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—kidney cancer	3.51e-07	6.88e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MTOR—kidney cancer	3.5e-07	6.84e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—kidney cancer	3.45e-07	6.75e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—kidney cancer	3.44e-07	6.73e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—kidney cancer	3.43e-07	6.72e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP1A1—kidney cancer	3.43e-07	6.72e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK3—kidney cancer	3.43e-07	6.71e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—kidney cancer	3.43e-07	6.7e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—kidney cancer	3.4e-07	6.66e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK3—kidney cancer	3.4e-07	6.65e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RAF1—kidney cancer	3.4e-07	6.65e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—kidney cancer	3.38e-07	6.62e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—kidney cancer	3.38e-07	6.62e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RELA—kidney cancer	3.38e-07	6.62e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—kidney cancer	3.38e-07	6.61e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—kidney cancer	3.37e-07	6.59e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—kidney cancer	3.36e-07	6.57e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	3.35e-07	6.56e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ITPR2—kidney cancer	3.35e-07	6.55e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—kidney cancer	3.34e-07	6.53e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MTOR—kidney cancer	3.31e-07	6.49e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—kidney cancer	3.3e-07	6.47e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—kidney cancer	3.3e-07	6.45e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—kidney cancer	3.29e-07	6.44e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—kidney cancer	3.28e-07	6.42e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1B—kidney cancer	3.28e-07	6.42e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—kidney cancer	3.28e-07	6.42e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK3—kidney cancer	3.27e-07	6.41e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—kidney cancer	3.27e-07	6.4e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—kidney cancer	3.27e-07	6.4e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK1—kidney cancer	3.26e-07	6.39e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.25e-07	6.37e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—kidney cancer	3.24e-07	6.33e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK1—kidney cancer	3.23e-07	6.33e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—kidney cancer	3.21e-07	6.29e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—kidney cancer	3.21e-07	6.28e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	3.2e-07	6.26e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JUN—kidney cancer	3.19e-07	6.25e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	3.17e-07	6.2e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—kidney cancer	3.16e-07	6.18e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—kidney cancer	3.13e-07	6.13e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—kidney cancer	3.13e-07	6.12e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JUN—kidney cancer	3.12e-07	6.11e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK1—kidney cancer	3.11e-07	6.1e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—kidney cancer	3.11e-07	6.09e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—kidney cancer	3.11e-07	6.09e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—kidney cancer	3.1e-07	6.07e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—kidney cancer	3.09e-07	6.06e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK3—kidney cancer	3.09e-07	6.05e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	3.09e-07	6.04e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—kidney cancer	3.08e-07	6.03e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—kidney cancer	3.06e-07	5.99e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—kidney cancer	3.05e-07	5.98e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ACHE—kidney cancer	3.05e-07	5.97e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—kidney cancer	3.05e-07	5.97e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—kidney cancer	3.04e-07	5.96e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—kidney cancer	3.04e-07	5.94e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—kidney cancer	3.02e-07	5.92e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK3—kidney cancer	3.02e-07	5.91e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—kidney cancer	3.02e-07	5.91e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—kidney cancer	3.01e-07	5.89e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1A1—kidney cancer	2.99e-07	5.85e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—kidney cancer	2.97e-07	5.82e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—kidney cancer	2.97e-07	5.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—kidney cancer	2.96e-07	5.8e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—kidney cancer	2.95e-07	5.77e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK1—kidney cancer	2.94e-07	5.76e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—kidney cancer	2.94e-07	5.76e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—kidney cancer	2.94e-07	5.75e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—kidney cancer	2.94e-07	5.75e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RAF1—kidney cancer	2.94e-07	5.75e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—kidney cancer	2.93e-07	5.73e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RELA—kidney cancer	2.92e-07	5.72e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—kidney cancer	2.9e-07	5.68e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SCARB1—kidney cancer	2.89e-07	5.65e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK1—kidney cancer	2.88e-07	5.63e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—kidney cancer	2.87e-07	5.62e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—kidney cancer	2.87e-07	5.61e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—kidney cancer	2.86e-07	5.61e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS1—kidney cancer	2.86e-07	5.6e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—kidney cancer	2.85e-07	5.57e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—kidney cancer	2.83e-07	5.54e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.82e-07	5.52e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.82e-07	5.52e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—kidney cancer	2.8e-07	5.49e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSMD7—kidney cancer	2.8e-07	5.49e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.79e-07	5.47e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	2.79e-07	5.46e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK1—kidney cancer	2.79e-07	5.45e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—kidney cancer	2.78e-07	5.44e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—kidney cancer	2.74e-07	5.36e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—kidney cancer	2.73e-07	5.34e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—kidney cancer	2.72e-07	5.32e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—kidney cancer	2.71e-07	5.31e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—kidney cancer	2.7e-07	5.29e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—kidney cancer	2.69e-07	5.26e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BCHE—kidney cancer	2.66e-07	5.2e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	2.64e-07	5.16e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—kidney cancer	2.63e-07	5.15e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—kidney cancer	2.63e-07	5.15e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.63e-07	5.14e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—kidney cancer	2.59e-07	5.06e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—kidney cancer	2.58e-07	5.05e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—kidney cancer	2.57e-07	5.02e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—kidney cancer	2.56e-07	5.02e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—kidney cancer	2.56e-07	5.01e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—kidney cancer	2.56e-07	5.01e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—kidney cancer	2.55e-07	5e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—kidney cancer	2.54e-07	4.97e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.54e-07	4.96e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—kidney cancer	2.51e-07	4.91e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	2.51e-07	4.91e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—kidney cancer	2.5e-07	4.88e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—kidney cancer	2.48e-07	4.85e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—kidney cancer	2.47e-07	4.83e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK1—kidney cancer	2.46e-07	4.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—kidney cancer	2.45e-07	4.79e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—kidney cancer	2.42e-07	4.73e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—kidney cancer	2.41e-07	4.72e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—kidney cancer	2.39e-07	4.67e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—kidney cancer	2.38e-07	4.66e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	2.37e-07	4.64e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—kidney cancer	2.34e-07	4.58e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK1—kidney cancer	2.33e-07	4.56e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—kidney cancer	2.32e-07	4.54e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.3e-07	4.49e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—kidney cancer	2.24e-07	4.38e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—kidney cancer	2.23e-07	4.37e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—kidney cancer	2.2e-07	4.3e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	2.18e-07	4.26e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—kidney cancer	2.13e-07	4.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—kidney cancer	2.12e-07	4.14e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—kidney cancer	2.12e-07	4.14e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—kidney cancer	2.11e-07	4.12e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—kidney cancer	2.1e-07	4.12e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—kidney cancer	2.1e-07	4.11e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—kidney cancer	2.08e-07	4.08e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—kidney cancer	2.06e-07	4.04e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—kidney cancer	2.06e-07	4.03e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—kidney cancer	2.04e-07	4e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—kidney cancer	2.02e-07	3.96e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—kidney cancer	2.02e-07	3.96e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK1—kidney cancer	2.01e-07	3.94e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—kidney cancer	2e-07	3.92e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—kidney cancer	1.95e-07	3.83e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—kidney cancer	1.94e-07	3.8e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—kidney cancer	1.9e-07	3.72e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.84e-07	3.61e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—kidney cancer	1.78e-07	3.49e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—kidney cancer	1.78e-07	3.48e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—kidney cancer	1.75e-07	3.42e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—kidney cancer	1.69e-07	3.31e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—kidney cancer	1.68e-07	3.28e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—kidney cancer	1.66e-07	3.25e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—kidney cancer	1.55e-07	3.04e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—kidney cancer	1.48e-07	2.9e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—kidney cancer	1.46e-07	2.86e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—kidney cancer	1.45e-07	2.84e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—kidney cancer	1.37e-07	2.69e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.26e-07	2.46e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—kidney cancer	1.1e-07	2.15e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—kidney cancer	1.09e-07	2.14e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.03e-07	2.02e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.02e-07	2e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—kidney cancer	9.56e-08	1.87e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.74e-08	1.32e-06	CbGpPWpGaD
